[1]何 芳.头孢哌酮钠舒巴坦钠联合甲硝唑治疗慢性盆腔炎的临床疗效及对盆腔炎性包块大小的影响[J].医学信息,2024,37(20):88-91.[doi:10.3969/j.issn.1006-1959.2024.20.016]
　HE Fang.Clinical Efficacy of Cefoperazone Sodium and Sulbactam Sodium Combined with Metronidazole in the Treatment of Chronic Pelvic Inflammatory Disease and its Effect on the Size of Pelvic Inflammatory Mass[J].Journal of Medical Information,2024,37(20):88-91.[doi:10.3969/j.issn.1006-1959.2024.20.016]
点击复制

头孢哌酮钠舒巴坦钠联合甲硝唑治疗慢性盆腔炎的临床疗效及对盆腔炎性包块大小的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
37卷
期数:
2024年20期
页码:
88-91
栏目:
论著
出版日期:
2024-10-15

文章信息/Info

Title:
Clinical Efficacy of Cefoperazone Sodium and Sulbactam Sodium Combined with Metronidazole in the Treatment of Chronic Pelvic Inflammatory Disease and its Effect on the Size of Pelvic Inflammatory Mass
文章编号:
1006-1959（2024）20-0088-04
作者:
何 芳
峡江县中医院妇产科，江西 峡江 331400
Author(s):
HE Fang
Department of Obstetrics and Gynecology,Xiajiang County Hospital of Traditional Chinese Medicine,Xiajiang 331400,Jiangxi,China
关键词:
慢性盆腔炎; 头孢哌酮钠舒巴坦钠; 头孢他啶; 甲硝唑; 盆腔炎性包块
Keywords:
Chronic pelvic inflammatory disease; Cefoperazone sodium and sulbactam sodium; Ceftazidime; Metronidazole; Pelvic inflammatory mass
分类号:
R711
DOI:
10.3969/j.issn.1006-1959.2024.20.016
摘要:
目的 研究头孢哌酮钠舒巴坦钠（CSSS）联合甲硝唑治疗慢性盆腔炎的临床疗效及对盆腔炎性包块大小的影响。方法 选取2020年12月-2023年3月峡江县中医院收治的62例慢性盆腔炎患者，经随机数字表法分为对照组（31例）和观察组（31例）。对照组给予头孢他啶联合甲硝唑治疗，观察组给予CSSS联合甲硝唑治疗，比较两组临床疗效、盆腔炎性包块面积、疼痛程度[视觉模拟评分（VAS）]、症状改善情况（下腹坠胀、白带增多、宫体压痛）、炎性指标[白细胞计数（WBC）、中性粒细胞比例（NEUT%）、C反应蛋白（CRP）]、复发情况。结果 观察组治疗总有效率为96.77%，高于对照组的83.87%（P＜0.05）；两组治疗后盆腔炎性包块面积、VAS评分均小于治疗前，且观察组治疗后盆腔炎性包块面积、VAS评分小于对照组（P＜0.05）；两组治疗后症状评分（下腹坠胀、白带增多、宫体压痛）低于治疗前，且观察组治疗后症状评分（下腹坠胀、白带增多、宫体压痛）低于对照组（P＜0.05）；两组治疗后WBC、NEUT%、CRP指标低于治疗前，且观察组治疗后WBC、NEUT%、CRP指标低于对照组（P＜0.05）；治疗后6个月，观察组复发率低于对照组（P＜0.05）。结论 CSSS联合甲硝唑治疗慢性盆腔炎效果良好，可缩小患者盆腔炎性包块，缓解其疼痛程度，减轻临床症状，下调炎症指标，降低复发风险。
Abstract:
Objective To study the clinical efficacy of ceftazidime or cefoperazone sodium and sulbactam sodium (CSSS) combined with metronidazole in the treatment of chronic pelvic inflammatory disease and its impact on the size of pelvic inflammatory masses.Methods A total of 62 patients with chronic pelvic inflammatory disease admitted to Xiajiang County Hospital of Traditional Chinese Medicine from December 2020 to March 2023 were selected and divided into control group (31 patients) and observation group (31 patients) by random number table method. The control group was treated with ceftazidime combined with metronidazole, and the observation group was treated with CSSS combined with metronidazole. The clinical efficacy, pelvic inflammatory mass area, pain degree [Visual Analogue Scale (VAS)], symptom improvement (lower abdominal bulge, leucorrhea increase, uterine tenderness), inflammatory index [white blood cell count (WBC), neutrophil ratio (NEUT%), C-reactive protein (CRP)] and recurrence were compared between the two groups.Results The total effective rate of treatment in the observation group was 96.77%, which was higher than 83.87% in the control group (P<0.05). After treatment, the area of pelvic inflammatory mass and VAS score in the two groups were smaller than those before treatment, and the area of pelvic inflammatory mass and VAS score in the observation group were smaller than those in the control group (P<0.05). After treatment, the symptom scores (lower abdominal bulge, leukorrhea increase, uterine body tenderness) of the two groups were lower than those before treatment, and the symptom scores (lower abdominal bulge, leukorrhea increase, uterine body tenderness) of the observation group were lower than those of the control group (P<0.05). The WBC, NEUT% and CRP indexes of the two groups after treatment were lower than those before treatment, and the WBC, NEUT% and CRP indexes of the observation group after treatment were lower than those of the control group (P<0.05). At 6 months after treatment, the recurrence rate of the observation group was lower than that of the control group (P<0.05).Conclusion CSSS combined with metronidazole is effective in the treatment of chronic pelvic inflammatory disease, which can reduce the pelvic inflammatory mass, relieve the pain degree, reduce the clinical symptoms, down-regulate the inflammatory index and reduce the risk of recurrence.

参考文献/References:

[1]袁绘钰,蔡丽萍.红外光炙治疗仪联合甲硝唑治疗慢性盆腔炎患者的临床疗效及对临床症状的影响[J].医学信息,2023,36(18):152-155.[2]Lin HW,Wang PH,Lee CY,et al.The Risk of Gynecologic and Urinary Tract Cancer with Pelvic Inflammatory Disease: A Population-Based Cohort Study[J].J Cancer,2019,10(1):28-34.[3]李代晓,应颖秋,杨丽,等.头孢哌酮舒巴坦治疗妇产科感染有效性和安全性的系统评价[J].中国医院用药评价与分析,2022,22(11):1361-1364.[4]王兰君,王慧玲,李梦琪.甲硝唑呋喃唑酮栓联合左氧氟沙星治疗慢性盆腔炎合并糖尿病的疗效[J].天津药学,2022,34(5):42-45.[5]于凤艳,颜新彦,霍叶琳.甲硝唑联合头孢曲松、多西环素治疗盆腔炎对细胞因子、免疫功能和血液流变学的影响[J].河北医药,2022,44(1):72-75.[6]赵新,刘生元.康妇炎胶囊联合甲硝唑对湿热蕴结型慢性盆腔炎患者炎症因子T细胞亚群及生活质量的影响[J].山西医药杂志,2021,50(24):3346-3349.[7]董兆琴,张娟,张桂莲.止痛化癥胶囊联合注射用头孢他啶治疗慢性盆腔炎的效果[J].中国医药导报,2021,18(26):85-89.[8]中华医学会妇产科学分会感染性疾病协作组.盆腔炎症性疾病诊治规范(2019修订版)[J].中华妇产科杂志,2019,54(7):433-437.[9]张缓,赵颖超,闫源渊.甲硝唑分别联合头孢呋辛、左氧氟沙星治疗慢性盆腔炎的疗效评估[J].贵州医药,2023,47(6):933-934.[10]Till SR,Nakamura R,Schrepf A,et al.Approach to Diagnosis and Management of Chronic Pelvic Pain in Women: Incorporating Chronic Overlapping Pain Conditions in Assessment and Management[J].Obstet Gynecol Clin North Am,2022,49(2):219-239.[11]李雪芹,胡淑瑞,陈晓芳.宫炎康胶囊联合头孢他啶治疗慢性盆腔炎的临床研究[J].现代药物与临床,2020,35(8):1663-1666.[12]周江,毛莉.头孢他啶针联合奥硝唑片对慢性盆腔炎患者血管内皮功能及相关免疫因子的影响[J].中国妇幼保健,2020,35(13):2376-2379.[13]马改大.注射用头孢哌酮钠舒巴坦钠的临床应用效果及不良反应[J].中国药物与临床,2020,20(7):1145-1146.[14]伊碧霞,朱敏,徐海霞,等.甲硝唑联合头孢曲松、多西环素治疗盆腔炎的临床疗效[J].中国新药与临床杂志,2020,39(1):26-30.[15]辛栋轶,于旭红,方芳,等.头孢哌酮钠舒巴坦钠微泵3 h静脉给药的临床疗效和经济学评价[J].药学研究,2020,39(10):609-613,620.[16]李静.甲硝唑联合头孢曲松和多西环素治疗盆腔炎的疗效评价[J].上海医药,2019,40(8):24-25,62.[17]李友霞,张岩,孙玉娟,等.月经期第二代头孢菌素与甲硝唑联用结合非月经期理疗治疗妇科盆腔炎性疾病的临床疗效分析[J].中国性科学,2019,28(11):89-92.[18]陈进芳,刘玉珠,韩一栩.保妇康栓联合头孢曲松钠、甲硝唑治疗慢性盆腔炎疗效分析[J].中华中医药学刊,2018,36(5):1231-1233.[19]林铃,程虹,韩柳,等.宫炎康胶囊联合头孢他啶对慢性盆腔炎患者血清炎症因子、血液流变学及生存质量的影响[J].现代生物医学进展,2021,21(16):3196-3200.[20]夏建宇,刘佳勋,於建鹏,等.头孢哌酮舒巴坦钠对淋病患者淋球菌改变及不良反应的临床观察[J].中国性科学,2018,27(5):129-132.

相似文献/References:

[1]柳 梅.头孢哌酮钠舒巴坦钠治疗糖尿病并发尿路感染的 临床效果观察[J].医学信息,2018,31(07):139.[doi:10.3969/j.issn.1006-1959.2018.07.047]
　LIU Mei.Clinical Efficacy of Cefoperazone Sodium and Sulbactam Sodium in Treatment of Diabetes Complicated with Urinary Tract Infection[J].Journal of Medical Information,2018,31(20):139.[doi:10.3969/j.issn.1006-1959.2018.07.047]
[2]沈孟杰.注射用头孢哌酮钠舒巴坦钠临床应用效果及 不良反应发生情况研究[J].医学信息,2018,31(12):131.[doi:10.3969/j.issn.1006-1959.2018.12.040]
　SHEN Meng-jie.Clinical Application and Adverse Reactions of Cefoperazone Sodium and Sulbactam Sodium for Injection[J].Journal of Medical Information,2018,31(20):131.[doi:10.3969/j.issn.1006-1959.2018.12.040]
[3]隋文峰,马海英,潘 雪.乌司他丁联合头孢哌酮钠舒巴坦钠注射剂治疗重症肺部感染的疗效[J].医学信息,2020,33(19):143.[doi:10.3969/j.issn.1006-1959.2020.19.044]
　SUI Wen-feng,MA Hai-ying,PAN Xue.The Efficacy of Ulinastatin Combined with Cefoperazone Sodium and Sulbactam Sodium Injection in the Treatment of Severe Pulmonary Infection[J].Journal of Medical Information,2020,33(20):143.[doi:10.3969/j.issn.1006-1959.2020.19.044]
[4]魏长斌.头孢哌酮钠舒巴坦钠对糖尿病合并尿路感染的疗效及安全性分析[J].医学信息,2021,34(14):151.[doi:10.3969/j.issn.1006-1959.2021.14.042]
　WEI Chang-bin.Analysis of the Efficacy and Safety of Cefoperazone Sodium and Sulbactam Sodium on Diabetes Complicated with Urinary Tract Infection[J].Journal of Medical Information,2021,34(20):151.[doi:10.3969/j.issn.1006-1959.2021.14.042]
[5]王天英.穴位贴敷联合阶段性护理对慢性盆腔炎患者康复状况及临床症状的影响[J].医学信息,2023,36(05):165.[doi:10.3969/j.issn.1006-1959.2023.05.034]
　WANG Tian-ying.Effect of Acupoint Application Combined with Staged Nursing on Rehabilitation and Clinical Symptoms of Patients with Chronic Pelvic Inflammatory Disease[J].Journal of Medical Information,2023,36(20):165.[doi:10.3969/j.issn.1006-1959.2023.05.034]
[6]袁绘钰,蔡丽萍.红外光炙治疗仪联合甲硝唑治疗慢性盆腔炎患者的临床疗效及对临床症状的影响[J].医学信息,2023,36(18):152.[doi:10.3969/j.issn.1006-1959.2023.18.030]
　YUAN Hui-yu,CAI Li-ping.Clinical Effect of Infrared Phototherapy Instrument Combined with Metronidazole in the Treatment of Patients with Chronic Pelvic Inflammatory Disease and its Effect on Clinical Symptoms[J].Journal of Medical Information,2023,36(20):152.[doi:10.3969/j.issn.1006-1959.2023.18.030]
[7]帅翠芳.整体护理联合中医综合护理对慢性盆腔炎患者健康行为、疼痛程度及疾病复发的影响[J].医学信息,2023,36(24):159.[doi:10.3969/j.issn.1006-1959.2023.24.037]
　SHUAI Cui-fang.Effect of Holistic Nursing Combined with Comprehensive Nursing of Traditional Chinese Medicine on Health Behavior, Pain Degree and Disease Recurrence in Patients with Chronic Pelvic Inflammatory Disease[J].Journal of Medical Information,2023,36(20):159.[doi:10.3969/j.issn.1006-1959.2023.24.037]
[8]晏 清,周 颖.中药灌肠方联合雷火灸治疗慢性盆腔炎的效果及对炎症因子的影响[J].医学信息,2024,37(11):116.[doi:10.3969/j.issn.1006-1959.2024.11.022]
　YAN Qing,ZHOU Ying.Effect of Traditional Chinese Medicine Enema Combined with Thunder Fire Moxibustion on Chronic Pelvic Inflammatory Disease and its Influence on Inflammatory Factors[J].Journal of Medical Information,2024,37(20):116.[doi:10.3969/j.issn.1006-1959.2024.11.022]
[9]彭维萍.健康教育联合穴位艾灸护理对急性盆腔炎患者临床症状及复发情况的影响[J].医学信息,2024,37(12):148.[doi:10.3969/j.issn.1006-1959.2024.12.034]
　PENG Wei-ping.Effect of Health Education Combined with Acupoint Moxibustion Nursing on Clinical Symptoms and Recurrence of Patients with Acute Pelvic Inflammatory Disease[J].Journal of Medical Information,2024,37(20):148.[doi:10.3969/j.issn.1006-1959.2024.12.034]

更新日期/Last Update: 1900-01-01